Overview

GBM represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.

Eligibility

Inclusion Criteria:

        Each participant must meet all of the following inclusion criteria to participate in this
        study:
          -  ≥ 18 years of age
          -  Diagnosis of glioblastoma multiforme
          -  Post-maximally safe surgical resection
          -  No prior radiation or systemic treatment for high grade glioma
          -  Able to tolerate PET/MRI scan with intravenous contrast
          -  Willing to provide informed consent
        Exclusion Criteria:
        All participants meeting any of the following exclusion criteria at baseline screening will
        be excluded from participation in this study:
          -  MRI contraindication
          -  Creatinine clearance < 30mL/min
          -  Inability to lie still for 60 minutes
          -  Gadolinium allergy
          -  Positive pregnancy test
          -  Breastfeeding
          -  Patient unable to follow the protocol for any reason